Ottawa, May 30, 2022 – Innovative Medicines Canada (IMC) is pleased to announce Alok Kanti, President and Chief Executive Officer of Bayer Canada, has been elected as Chair of its Board of Directors.
“Alok has played an instrumental role as an IMC Board Member for the last five years, working tirelessly to advance policies that increase patient access to medicines, promote a robust life sciences sector in Canada, and foster collaboration across governments, non-profit organizations, and private sector companies for the benefit of all Canadians,” said Pamela Fralick, President of Innovative Medicines Canada. “His work as Vice-Chair of the Health Research Foundation Board of Directors also speaks to his leadership and commitment to research-driven health systems resiliency in Canada.”
Mr. Kanti started his professional career with Bayer in June 1994 and since has gained a wealth of experience in regional management, commercial operations, strategic marketing and country division management. Prior to being appointed as President and CEO of Bayer Canada in 2015, Mr. Kanti was Managing Director of Bayer HealthCare China, where he helped Bayer build a leading position in the world’s third-largest health-care market.
“Throughout the pandemic, governments, stakeholders and industry have come together like never before to put the health of Canadian patients first,” said Alok Kanti, President and CEO of Bayer Canada. “As Chair of IMC’s Board of Directors, I’m committed to ensuring this spirit of collaboration continues to improve access to all innovative medicines and vaccines for Canadians.”
Mr. Kanti will serve as Board Chair until November 2023.
About Innovative Medicines Canada
Innovative Medicines Canada is the national association representing the voice of Canada’s innovative pharmaceutical industry. The association advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians and supports the members’ commitment to being a valued partner in the Canadian healthcare system. The association represents 49 companies who invest nearly $1.4 billion in R&D annually, fueling Canada’s knowledge-based economy, while contributing $8 billion to Canada’s economy. Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.
For further information:
Director, Media Relations & Content